---
title: "External Resources"
output: html_document
---

### General Reference Texts

## Statistical Analysis

The cut-off values to determine whether a subject has *POSITIVE* or *NEGATIVE* ADA result are the screening cutpoint and confirmatory cutpoint. Please see here for more information:

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.

https://www.ncbi.nlm.nih.gov/pubmed/18993008

Other documents include:

The quintessence of immunogenicity reporting for biotherapeutics

http://www.nature.com/nbt/journal/v33/n4/full/nbt.3181.html?message-global=remove

Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products

https://www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf

Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides â€“ Harmonized Terminology and Tactical Recommendation

https://www.ncbi.nlm.nih.gov/pubmed/24764037

http://www.e-i-p.eu/wp-content/uploads/2013/01/Devanarayan_EIP_Leiden_2009.pdf

Cut points in immunogenicity assays are used to classify future specimens into anti-drug antibody (ADA) positive or negative. Five phenomena may complicate the statistical cut point estimation and are further explained here:

https://www.ncbi.nlm.nih.gov/pubmed/25733352